3,4-DI-(4-(TRIFLUOROMETHYL)PHENYL)FUROXAN


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YZCVIJHTVDCDCM-UHFFFAOYSA-N
Smiles	[O-][n+]1onc(c2ccc(cc2)C(F)(F)F)c1c3ccc(cc3)C(F)(F)F
InChI	InChI=1S/C16H8F6N2O2/c17-15(18,19)11-5-1-9(2-6-11)13-14(24(25)26-23-13)10-3-7-12(8-4-10)16(20,21)22/h1-8H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H8F6N2O2
Molecular Weight	374.24
AlogP	2.72
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	51.49
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Blumeria graminis at 250 ppm relative to control	Blumeria graminis	17.0 %
Fungicidal activity against Phytophthora infestans at 250 ppm relative to control	Phytophthora infestans	53.0 %
Fungicidal activity against Puccinia recondita at 250 ppm relative to control	Puccinia recondita	0.0 %
Fungicidal activity against Botryotinia fuckeliana at 250 ppm relative to control	Botryotinia fuckeliana	0.0 %
Fungicidal activity against Rhizoctonia solani at 250 ppm relative to control	Rhizoctonia solani	11.0 %
Fungicidal activity against Magnaporthe oryzae at 250 ppm relative to control	Magnaporthe oryzae	6.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2271493
PubChem	479780

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).